Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
December 18, 2025
Congrats to Peel’s CEO for his talk at Colorectal Cancer Alliance‘s 2025 CureCRC Summit. PEEL-224 offers a new approach to treating cancer with better efficacy and less toxicity. Our company looks forward to continuing to test PEEL-224 in patients on multiple clinical trials.
PEEL-224 offers a new way of treating aggressive cancers like metastatic CRC. PEEL-224 is a new cancer medicine with a delivery optimized, novel TOPO1 inhibitor payload showing early promise for patients. Excited to introduce a new way to treat cancer with better efficacy and less toxicity.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
